Company profile: Tizona Therapeutics
1.1 - Company Overview
Company description
- Provider of next-generation immunotherapies, including TTX-080, an investigational antibody targeting HLA-G evaluated as monotherapy and in combination in patients with advanced cancers; TTX-030, a monoclonal antibody inhibiting CD39 studied with an approved anti-PD-1 agent and standard chemotherapy in adults with advanced cancer; and TZ-040, a pre-clinical program anticipated to enter IND-enabling studies targeting novel immuno-modulatory molecules.
Products and services
- TTX-030: A clinical-stage monoclonal antibody that inhibits CD39, studied with an approved anti-PD-1 agent plus standard chemotherapy in adults with advanced cancer
- TTX-080: An investigational-stage antibody targeting HLA-G, evaluated as monotherapy and in combination with other agents in patients with advanced cancers
- TZ-040: A pre-clinical program, anticipated for IND-enabling studies, architected to target novel immuno-modulatory molecules for next-generation immunotherapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tizona Therapeutics
IFM Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule therapeutics targeting innate immune pathways, including antagonists of the cGAS-STING pathway for diseases caused by abnormal cytosolic DNA signaling, antagonists of NLR proteins to reduce cytokine production and inflammatory signaling in various diseases, and AIM2 agonists to activate the inflammasome and promote immune responses against certain tumor types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IFM Therapeutics company profile →
Acambis
HQ: United Kingdom
Website
- Description: Provider of vaccine research, development and manufacturing for the prevention and treatment of infectious diseases in Europe and North America, offering ACAM2000, a smallpox vaccine for emergency-use stockpiling, and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acambis company profile →
MultiCell Technologies
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MultiCell Technologies company profile →
NextPoint Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics to treat cancer, including NPX887 targeting HHLA2 and NPX267 targeting KIR3DL3 to reactivate exhausted T and NK cells in HHLA2+ solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NextPoint Therapeutics company profile →
Bird Rock Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development of novel biologic therapeutics and immuno-inflammatory regulators, focused on meeting the medical and commercial needs of China’s patients and healthcare system with potential global impact, including RYI-008, an extremely potent monoclonal antibody highly selective to IL-6.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bird Rock Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tizona Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tizona Therapeutics
2.2 - Growth funds investing in similar companies to Tizona Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tizona Therapeutics
4.2 - Public trading comparable groups for Tizona Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →